Skip to main content

Table 1 Patient demographics stratified by sinus surgery and biologic use

From: Biologic use and treatment patterns in patients with chronic rhinosinusitis with nasal polyps: a US real-world study

Demographics

All patients

All patients

Sinus surgery

No sinus surgery

N = 5997

Biologic use

No biologic use

P-value

Biologic use†

No biologic use

P-value

Biologic use

No biologic use

P-value

N = 642

N = 5355

N = 55

N = 420

N = 587

N = 4935

Age, years, mean (SD)

48.1 (13.1)

48.8 (11.4)

48.0 (13.3)

0.171

45.4 (11.4)

45.7 (13.9)

0.886

49.1 (11.4)

48.2 (13.2)

0.129

Age group, years, n (%)

       

18–34

977 (16.3)

78 (12.1)

899 (16.8)

0.002

12 (21.8)

96 (22.9)

0.741

66 (11.2)

803 (16.3)

0.002

35–44

1227 (20.5)

148 (23.1)

1079 (20.1)

14 (25.5)

80 (19.0)

134 (22.8)

999 (20.2)

45–54

1697 (28.3)

192 (29.9)

1505 (28.1)

15 (27.3)

118 (28.1)

177 (30.2)

1387 (28.1)

55–64

1731 (28.9)

201 (31.3)

1530 (28.6)

13 (23.6)

101 (24.0)

188 (32.0)

1429 (29)

65–74

229 (3.8)

15 (2.3)

214 (4.0)

1 (1.8)

17 (4.0)

14 (2.4)

197 (4.0)

 ≥ 75

136 (2.3)

8 (1.2)

128 (2.4)

0 (0)

8 (1.9)

8 (1.4)

120 (2.4)

Male, n (%)

3472 (57.9)

335 (52.2)

3137 (58.6)

0.002

27 (49.1)

255 (60.7)

0.099

308 (52.5)

2882 (58.4)

0.006

Geographic region, n (%)

          

Northeast

1043 (17.4)

104 (16.2)

939 (17.5)

0.253

6 (10.9)

67 (16.0)

0.501

98 (16.7)

872 (17.7)

0.296

North Central

1426 (23.8)

164 (25.5)

1262 (23.6)

 

10 (18.2)

99 (23.6)

 

154 (26.2)

1163 (23.6)

 

South

2685 (44.8)

278 (43.3)

2407 (44.9)

 

28 (50.9)

194 (46.2)

 

250 (42.6)

2213 (44.8)

 

West

821 (13.7)

96 (15.0)

725 (13.5)

 

11 (20.0)

56 (13.3)

 

85 (14.5)

669 (13.6)

 

Unknown

22 (0.4)

0 (0)

22 (0.4)

 

0 (0)

4 (1.0)

 

0 (0)

18 (0.4)

 

Residence, n (%)

          

Urban

5347 (89.2)

591 (92.1)

4756 (88.8)

0.021

51 (92.7)

365 (86.9)

0.617

540 (92.0)

4391 (89.0)

0.044

Rural

628 (10.5)

51 (7.9)

577 (10.8)

 

4 (7.3)

51 (12.1)

 

47 (8.0)

526 (10.7)

 

Unknown

22 (0.4)

0 (0)

22 (0.4)

 

0 (0)

4 (1.0)

 

0 (0)

18 (0.4)

 

Insurance plan type, n (%)

          

Comprehensive/indemnity

251 (4.2)

30 (4.7)

221 (4.1)

0.943

0 (0)

16 (3.8)

0.629

30 (5.1)

205 (4.2)

0.891

EPO/PPO

2964 (49.4)

317 (49.4)

2647 (49.4)

 

26 (47.3)

209 (49.8)

 

291 (49.6)

2438 (49.4)

 

POS/POS with capitation

392 (6.5)

42 (6.5)

350 (6.5)

 

4 (7.3)

25 (6.0)

 

38 (6.5)

325 (6.6)

 

HMO

851 (14.2)

96 (15.0)

755 (14.1)

 

10 (18.2)

55 (13.1)

 

86 (14.7)

700 (14.2)

 

CDHP/HDHP

1431 (23.9)

147 (22.9)

1284 (24.0)

 

15 (27.3)

109 (26.0)

 

132 (22.5)

1175 (23.8)

 

Other/unknown

108 (1.8)

10 (1.6)

98 (1.8)

 

0 (0)

6 (1.4)

 

10 (1.7)

92 (1.9)

 

Payer, n (%)

          

Commercial

5628 (93.8)

618 (96.3)

5010 (93.6)

0.007

54 (98.2)

395 (94.0)

0.342

564 (96.1)

4615 (93.5)

0.015

Medicare supplemental

369 (6.2)

24 (3.7)

345 (6.4)

 

1 (1.8)

25 (6.0)

 

23 (3.9)

320 (6.5)

 
  1. Demographics and medical insurance were measured on the earliest CRSwNP diagnosis date during the patient identification period (6/30/2018–6/30/2019). Patients were stratified by biologic and non-biologic use during the observation period (7/1/2019–6/30/2020). P-values in bold signify P < 0.05 for comparison within individual categories for biologic versus non-biologic use in each cohort (i.e., all patients, sinus surgery, no sinus surgery)
  2. CDHP, consumer-driven health plan; CRSwNP, chronic rhinosinusitis with nasal polyps; EPO, exclusive provider organization; HDHP, high deductible health plan; HMO, health maintenance organization; POS, point of service; PPO, preferred provider organization; SD standard deviation
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us